Board of Directors
Colin Hill is a leading voice in health care technology and precision medicine and brings impressive leadership experience in commercializing machine learning technologies in the biopharmaceutical and managed care industries. Mr. Hill co-founded GNS Healthcare Inc. and has since served as CEO. He is also the chairman of Gene Network Sciences, Inc., the parent company of GNS Healthcare.
Mr. Hill serves on the board of PPD. He is a founding board member of TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation dedicated to the advancement of personalized medicine. In 2016, he was appointed by Massachusetts Gov. Charlie Baker to the Massachusetts Digital Health Council.
Mr. Hill was a founding member of the board of directors of AesRx, a biopharmaceutical company dedicated to the development of new treatments for sickle cell disease (acquired by Baxter in 2014). He was the founding chairman of O’Reilly Media’s Strata Rx in 2012, the first health care big data conference in the industry. In 2004, Mr. Hill was named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35.
He is a frequent speaker at national and international scientific and industry conferences and has appeared in numerous publications and television programs, including The Wall Street Journal, CNBC’s Morning Call and SquawkBox, Nature, The Boston Globe, Politico, Forbes, Wired and The Economist.
He graduated from Virginia Tech with a degree in physics and earned master’s degrees in physics from both McGill University and Cornell University.